Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
NeoImmuneTech
National Cancer Institute (NCI)
Penn State University
Baylor College of Medicine
M.D. Anderson Cancer Center
University of Alabama at Birmingham
AstraZeneca
AstraZeneca
Takeda
Eli Lilly and Company
Seagen Inc.
NantCell, Inc.
Sanofi
Pfizer
Hoffmann-La Roche
Incyte Corporation
National Cancer Institute (NCI)
CytoDyn, Inc.
Alaunos Therapeutics
Palleon Pharmaceuticals, Inc.
University of Texas Southwestern Medical Center
Incyte Corporation
Mayo Clinic
M.D. Anderson Cancer Center
Formation Biologics
M.D. Anderson Cancer Center
Numab Therapeutics AG
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Precirix
Weill Medical College of Cornell University
Cedars-Sinai Medical Center
Washington University School of Medicine
NextCure, Inc.
Canadian Cancer Trials Group
Providence Health & Services
Intensity Therapeutics, Inc.
M.D. Anderson Cancer Center
Karolinska Institutet
BeiGene
Celltrion
University of Miami
Deciphera Pharmaceuticals, LLC
Syndax Pharmaceuticals
National Cancer Institute (NCI)
Sellas Life Sciences Group
Abramson Cancer Center at Penn Medicine